Skip to content
Medical Health Aged Care

Progress on new Aged Care Act a step in the right direction

Dementia Australia 2 mins read

Dementia Australia welcomes the release of the exposure draft of the new Aged Care Act.

Maree McCabe AM, CEO Dementia Australia welcomes the commitment by the Albanese Government to move towards a human rights-based approach by putting older people at the centre of the aged care system.

“More than two-thirds (68.1%) of aged care residents have moderate to severe cognitive impairment and 2 in 3 people with dementia live in the community,” Ms McCabe said.

“With this high prevalence, there must be a focus on people living with dementia when it comes to aged care services, both in home care and residential aged care.

“Dementia Australia will be reviewing the draft legislation to ensure it responds to the needs of people living with dementia, their families and carers and is consistent with our submission to the previous consultation earlier this year.”

Key features of the proposed Act include creating a single entry-point to make access to the aged care system easier, introducing strengthened Aged Care Quality Standards, strengthening the powers of the Aged Care Quality and Safety Commission and introducing criminal penalties that may apply in situations where service providers breach the law.

“We will share this information with people living with dementia, their families and carers and ensure they are supported to participate in the consultation process,” Ms McCabe said.

“I encourage older people, their families and the community to register for the Older Persons Advocacy Network (OPAN) webinar on 9 January 2024, “What’s at Stake?” where the Exposure Draft of the new Aged Care Act will be discussed.”

Register here for the 9 January 2024 webinar, 1:00pm – 2:30pm AEDT.

“Dementia Australia looks forward to working closely with the government to improve the health, care and lifestyle outcomes and experiences for people of all ages, living with all forms of dementia, and their families and carers,” Ms McCabe said.

To find out more, visit www.health.gov.au/aged-care-act-consultation

Dementia Australia is the source of trusted information, education and services for the estimated more than 400,000 Australians living with dementia, and the more than 1.5 million people involved in their care. We advocate for positive change and support vital research. We are here to support people impacted by dementia, and to enable them to live as well as possible. No matter how you are impacted by dementia or who you are, we are here for you.

For support, please contact the National Dementia Helpline on 1800 100 500. An interpreter service is available. The National Dementia Helpline is funded by the Australian Government. People looking for information can also visit dementia.org.au

-Ends-

Media contacts: Gabrielle Prabhu [email protected] 0447 253 583

When talking or writing about dementia please refer to Dementia-Friendly Language Guidelines.

Note to Editors:

We request, where possible, details for the National Dementia Helpline 1800 100 500 appear alongside news stories about dementia, as these stories often prompt questions or concerns:

If this story has prompted any questions or concerns, please call the National Dementia Helpline 1800 100 500 (24 hours, 7 days a week) or visit dementia.org.au. 

More from this category

  • Biotechnology, Medical Health Aged Care
  • 10/04/2026
  • 11:12
Aravax

Aravax Strengthens Board with Appointments of Carsten Hellmann and Andrew Oxtoby

Aravax, a clinical-stage biotechnology company developing next-generation, disease-modifyingimmunotherapies for food allergy, today announces two additions to its Board of Directors, former CEO of ALK-Abello A/S, Carsten Hellmann and former Chief Commercial Officer of Aimmune Therapeutics, Andrew Oxtoby. Collectively, Carsten and Andrew bring to Aravax exceptionally deep experience from the pharmaceutical industry and, specifically, the allergy therapeutics field. Andrew has deep pharmaceutical industry expertise spanning development, product launch, fundraising and exits from working with large and small companies in the U.S. and Europe. As Chief Commercial Officer he built the global commercial organisation for the approval and launch in the US…

  • Medical Health Aged Care, Political
  • 10/04/2026
  • 09:25
McKell Institute

Australians skipping doses, taking expired medication as prices balloon despite ‘Cheaper Medicines’

Australians are skipping doses, taking expired medication and going without groceries to afford medicines prescribed by their doctors because they aren’t covered by Labor’s landmark Cheaper Medicines policy, new research from the McKell Institute has revealed. McKell’s new report Still Out of Pocket found 43 per cent of Australians have been prescribed medicines which aren’t on the PBS. The Cheaper Medicines policy only covers medicines listed on the PBS. 24 per cent of all people prescribed medicines outside the PBS do not purchase the medicine at all, while 16 per cent say they are forced to go without essentials, like…

  • Medical Health Aged Care
  • 10/04/2026
  • 09:00
Neuroscience Research Australia (NeuRA)

EXPERT ALERT: ‘Bridge the Gap’ this World Parkinson’s Day

One Aussie is diagnosed with Parkinson’s Disease every 40 minutes. It’s the fastest growing neurological condition in the world and the second most common in Australia, after dementia. World Parkinson’s Day on 11 April aims to raise awareness of the disease, reduce stigma and advocate for better care and research support. Neuroscience Research Australia (NeuRA) has a team of experts, including clinician researchers, working to improve our understanding, diagnosis and treatment of Parkinson’s. They are available to speak on the importance of World Parkinson’s Day, providing comment on: Current research projects Improving understanding of Parkinson’s Disease, including its symptoms and…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.